LB Pharmaceuticals Files 8-K with Bylaw Amendments
Ticker: LBRX · Form: 8-K · Filed: Sep 12, 2025 · CIK: 1691082
Sentiment: neutral
Topics: corporate-governance, filing
TL;DR
LB Pharma filed an 8-K on 9/12/25 for bylaw changes and exhibits.
AI Summary
LB Pharmaceuticals Inc. filed an 8-K on September 12, 2025, reporting amendments to its articles of incorporation or bylaws and submitting financial statements and exhibits. The company, incorporated in Delaware, has its principal executive offices at One Pennsylvania Plaza, Suite 1025, New York, NY 10119.
Why It Matters
This filing indicates potential changes to LB Pharmaceuticals' corporate governance or operational structure, which could impact its strategic direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain any immediate negative financial or operational news.
Key Numbers
- 001-42831 — Commission File Number (Identifies the company's SEC filing history.)
- 81-1854347 — I.R.S. Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- LB Pharmaceuticals Inc (company) — Registrant
- September 12, 2025 (date) — Date of Report
- One Pennsylvania Plaza, Suite 1025 New York, NY 10119 (address) — Principal executive offices
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific amendments were made to the articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary information of the 8-K.
What financial statements and exhibits are included with this filing?
The filing states that financial statements and exhibits are included, but their specific content is not detailed in the provided text.
When was LB Pharmaceuticals Inc. incorporated?
LB Pharmaceuticals Inc. was incorporated in Delaware.
What is the principal executive office address for LB Pharmaceuticals Inc.?
The principal executive offices are located at One Pennsylvania Plaza, Suite 1025, New York, NY 10119.
What is the company's fiscal year end?
The company's fiscal year ends on December 31st (1231).
Filing Stats: 618 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2025-09-12 16:06:50
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LBRX The Nasdaq
Filing Documents
- d32696d8k.htm (8-K) — 26KB
- d32696dex31.htm (EX-3.1) — 29KB
- 0001193125-25-202195.txt ( ) — 181KB
- lbrx-20250912.xsd (EX-101.SCH) — 2KB
- lbrx-20250912_lab.xml (EX-101.LAB) — 19KB
- lbrx-20250912_pre.xml (EX-101.PRE) — 12KB
- d32696d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 3.1 Amended and Restated Certificate of Incorporation of the Registrant. 3.2 Amended and Restated Bylaws of the Registrant (incorporated herein by reference to Exhibit 3.4 to the Registrant's Registration Statement on Form S-1 (File No. 333-289812), filed with the Commission on August 22, 2025). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LB Pharmaceuticals Inc By: /s/ Heather Turner Heather Turner Chief Executive Officer Dated: September 12, 2025